DEF: MaxCyte Seeks Stockholder Approval for Equity Plan Amendment and AIM Delisting

MaxCyte is asking stockholders to approve an amendment to its equity incentive plan and to delist from the AIM market of the London Stock Exchange.

Summary

• MaxCyte, Inc. is holding its Annual Meeting of Stockholders on June 18, 2025, to vote on several proposals.
• The proposals include the election of three Class I directors, an amendment to the 2022 Equity Incentive Plan to increase the number of issuable shares by 2,950,000, and the cancellation of the company's admission to trading on the AIM market of the London Stock Exchange.
• Stockholders will also vote on ratifying the selection of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approving the adjournment of the Annual Meeting if necessary to solicit additional proxies.
• The Board of Directors recommends voting in favor of all proposals.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting information in a neutral and factual manner. The recommendations are positive, but the overall tone is informational.

Positives

• The proposed amendment to the equity incentive plan will allow the company to continue granting stock options, restricted stock unit awards, and other awards to employees, consultants, and directors.
• The AIM delisting is expected to enhance the liquidity of trading in the common stock by consolidating trading volume on Nasdaq.
• The AIM delisting will reduce duplicative compliance costs associated with maintaining listings on both AIM and Nasdaq.

Negatives

• If the AIM Delisting Proposal is passed, stockholders will no longer be able to buy and sell the common stock on AIM after Wednesday, June 25, 2025.
• Following the announcement, and prior to the effective date, of the AIM Delisting, sales of the common stock could have a negative effect on the value of the common stock as well as the trading price of the common stock on AIM and Nasdaq.

Risks

• If the proposal to increase the number of shares issuable under the 2022 Equity Incentive Plan is not approved, the company may face challenges with employee retention and recruitment.
• The AIM delisting could negatively impact stockholders who prefer trading on the AIM market.
• The company's success depends on its ability to maintain a competitive position in retaining and motivating its employees, consultants, and directors.

Future Outlook

The company intends to continue to be listed on Nasdaq with no interruption in trading activity.

Management Comments

• The Board believes that it is no longer in the best interests of the Company or its stockholders as a whole for the Company to retain admission of the common stock to trading on AIM.

Industry Context

The document does not provide specific industry context beyond the company's operations in the biopharmaceutical sector.

Related Party Transactions

• On January 1, 2024, the company entered into a Consulting Agreement with Apalachee, pursuant to which Apalachee will provide certain executive advisory and consulting services to the Company.
• Mr. Balthrop, a member of our Board, is the founder and principal of Apalachee and the individual primarily responsible for providing services to the Company under the Consulting Agreement.

Stakeholder Impact

• Stockholders will be impacted by the decisions made regarding the equity incentive plan and the AIM delisting.
• Employees, consultants, and directors may be affected by changes to the equity incentive plan.
• The AIM delisting could impact stockholders who prefer trading on that market.

Next Steps

• Stockholders are encouraged to vote on the proposals.
• The company will proceed with the AIM delisting if the proposal is approved.
• The company will file a registration statement on Form S-8 with the SEC to register the additional shares available for issuance under the 2022 Plan if the amendment is approved.

Key Dates

Keywords

proxy statement, annual meeting, equity incentive plan, AIM delisting, directors, stockholders, MaxCyte, shares